↓ Skip to main content

Activation of Tumor-Cell STING Primes NK-Cell Therapy

Overview of attention for article published in Cancer Immunology Research, June 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
22 tweeters

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Activation of Tumor-Cell STING Primes NK-Cell Therapy
Published in
Cancer Immunology Research, June 2022
DOI 10.1158/2326-6066.cir-22-0017
Pubmed ID
Authors

Erik H. Knelson, Elena V. Ivanova, Mubin Tarannum, Marco Campisi, Patrick H. Lizotte, Matthew A. Booker, Ismail Ozgenc, Moataz Noureddine, Brittany Meisenheimer, Minyue Chen, Brandon Piel, Nathaniel Spicer, Bonje Obua, Cameron M. Messier, Erin Shannon, Navin R. Mahadevan, Tetsuo Tani, Pieter J. Schol, Anna M. Lee-Hassett, Ari Zlota, Ha V. Vo, Minh Ha, Arrien A. Bertram, Saemi Han, Tran C. Thai, Corinne E. Gustafson, Kartika Venugopal, Timothy J. Haggerty, Thomas P. Albertson, Antja-Voy Hartley, Pinar O. Eser, Ze-Hua Li, Israel Cañadas, Marina Vivero, Assunta De Rienzo, William G. Richards, Adnan O. Abu-Yousif, Vicky A. Appleman, Richard C. Gregory, Alexander Parent, Neil Lineberry, Eric L. Smith, Pasi A. Jänne, Juan J. Miret, Michael Y. Tolstorukov, Rizwan Romee, Cloud P. Paweletz, Raphael Bueno, David A. Barbie

Abstract

Activation of the stimulator of interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding of the mechanism of action of STING agonists in human tumors is key to developing therapeutic combinations that activate effective innate antitumor immunity. Here, we report that malignant pleural mesothelioma cells robustly express STING and are responsive to STING agonist treatment ex vivo. Using dynamic single-cell RNA sequencing of explants treated with a STING agonist we observed CXCR3 chemokine activation primarily in tumor cells and cancer-associated fibroblasts, as well as T-cell cytotoxicity. In contrast, primary NK cells resisted STING agonist-induced cytotoxicity. STING agonists enhanced migration and killing of NK cells and mesothelin-targeted chimeric antigen receptor (CAR)-NK cells, improving therapeutic activity in patient-derived organotypic tumor spheroids. These studies reveal the fundamental importance of using human tumor samples to assess innate and cellular immune therapies. By functionally profiling mesothelioma tumor explants with elevated STING expression in tumor cells, we uncovered distinct consequences of STING agonist treatment in humans that support testing combining STING agonists with NK and CAR-NK cell therapies.

Twitter Demographics

The data shown below were collected from the profiles of 22 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 33%
Student > Master 1 17%
Student > Bachelor 1 17%
Student > Doctoral Student 1 17%
Unknown 1 17%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 50%
Immunology and Microbiology 1 17%
Engineering 1 17%
Unknown 1 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 August 2022.
All research outputs
#2,284,915
of 21,747,565 outputs
Outputs from Cancer Immunology Research
#233
of 1,340 outputs
Outputs of similar age
#45,826
of 338,687 outputs
Outputs of similar age from Cancer Immunology Research
#7
of 32 outputs
Altmetric has tracked 21,747,565 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,340 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,687 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.